Beth Scott Email & Phone Number

Thousand Oaks, Ca, Us

Rare Disease Business Unit In my role at Amgen previously Horizon, I lead strategic medical affairs for Thyroid Eye Disease (TED) and TEPEZZA, driving impactful medical and field operations. Leading a multidisciplinary team of board-certified specialists across Ophthalmology, Endocrinology, Neurotology, and Immunology, along with a 27-member Medical Science Liaison (MSL) Field Team, I ensure seamless alignment with medical and business objectives.I pioneered the development of a 12-quarter Evidence Generation Plan, identifying data gaps and executing 40 priority studies that produced 10-15 publications per quarter in peer-reviewed forums. This optimized product differentiation and enhanced TEPEZZA's benefit-risk profile. I also spearheaded a Launch Medical Readiness Plan, integrating cross-functional approaches to drive TED growth World Wide, engaging US & International healthcare professionals for Global expansion, payors, and patients to reinforce product lifecycle management and bring medicine to those with rare disease who are most in need of treatment.A significant aspect of my role has been leading digital transformation within Medical Affairs, where I have integrated advanced technologies such as social listening, HCP and patient journey mapping, virtual thought leader engagement, multi-channel education, shared medical information platforms, and omni-channel dissemination of evidence generation data. These initiatives have dramatically increased our scientific share of voice, amplifying the reach and impact of our evidence-based communications.

Dublin, Ireland, Ie

Rare Disease Business Unit In my role at Horizon, I lead strategic medical affairs for Thyroid Eye Disease (TED) and TEPEZZA, driving impactful medical and field operations. Leading a multidisciplinary team of board-certified specialists across Ophthalmology, Endocrinology, Neurotology, and Immunology, along with a 27-member Medical Science Liaison (MSL) Field Team, I ensure seamless alignment with medical and business objectives.I pioneered the development of a 12-quarter Evidence Generation Plan, identifying data gaps and executing 40 priority studies that produced 10-15 publications per quarter in peer-reviewed forums. This optimized product differentiation and enhanced TEPEZZA's benefit-risk profile. I also spearheaded a Launch Medical Readiness Plan, integrating cross-functional approaches to drive TED growth World Wide, engaging US & International healthcare professionals for Global expansion, payors, and patients to reinforce product lifecycle management and bring medicine to those with rare disease who are most in need of treatment.A significant aspect of my role has been leading digital transformation within Medical Affairs, where I have integrated advanced technologies such as social listening, HCP and patient journey mapping, virtual thought leader engagement, multi-channel education, shared medical information platforms, and omni-channel dissemination of evidence generation data. These initiatives have dramatically increased our scientific share of voice, amplifying the reach and impact of our evidence-based communications.

New York, New York, Us

At Eyenovia, I developed an innovative Regulatory Affairs, Medical Affairs and Pharmacovigilance structure, contributing to the clinical development of ophthalmic biopharmaceutical products, including drug/device combinations. Collaborating with the Chief Medical Officer, I balanced FDA compliance with marketing strategies, securing two collaboration agreements with Arctic Vision and Bausch Health that yielded over $90 million in milestone payments. My regulatory leadership and evidence generation strategies positioned Eyenovia for success in a competitive market.

New York, New York, Us

Leads a high-performance Medical Affairs function for this clinical stage ophthalmic biopharmaceutical company. Exceptional ophthalmic, medical, and clinical design expertise. Strong compliance mindset and excellent understanding of relevant GCP, ICH and FDA/EMA regulations. Defines and establishes company-wide vision, building an operational Medical Affairs Organization in support of product and program expansion. Establishes and oversees relevant systems and processes to support business needs and ensure compliant, consistent, and ethical operations, including for medical-scientific communications and publications strategies. Drove Plans and developed programs involving internal and external medical education, medical grants, medical information, pharmacovigilance, investigator-initiated trials, publications, and advocacy meeting key strategic company needs. Led Evidence Generation of Pivotal Phase 3B Trials + 4 Clinical Studies. Chief Medical Reviewer establishing MLR framework and approval process in compliance with Regulatory Guidelines. Developed Advocacy by establishing and nurturing relationships with KOLs as external partners, expert investigators, professional associations and investors for Business Development and inLicensing BD&L.

As CEO, I provided strategic consulting to C-suite executives and start-ups, focusing on pre-launch readiness and regulatory compliance for diagnostic and therapeutic innovations. I built partnerships between academia and industry through grant writing and thought leadership, advancing medical education and research. My patient-centric approach, combined with regulatory oversight, helped organizations effectively bring pioneering medical solutions to market.

I led the medical strategy for the launch of Rhopressa and Rocklatan, facilitating their regulatory approval including an FDA Panel Meeting, and commercial success. My payor engagement efforts achieved rapid insurance coverage, with 85% commercial and 42% Medicare Part D access within six months. Additionally, I established a global Key Opinion Leader (KOL) network and created a Medical Information Call Center to streamline communications with stakeholders. Created KOL Mapping & KOL Engagement plan to establish relationships with 50+ expert clinician scientists and partnerships with Clinical Research Chairs and Chief Academic Officers of 24 institutions. Served as Medical Affairs Chief Scientific Expert for Payor engagement on all National and Regional Accounts, gaining market access to plan coverage.

Tokyo, Jp, Jp

I was responsible for the medical affairs strategy for the global launch of Xiidra™. I led Phase IV evidence generation strategies, built strategic partnerships with over 100 healthcare professionals, and developed KOL mapping to amplify scientific dialogue. My cross-functional leadership ensured that Xiidra was well-positioned for success in a highly competitive market. Robustly launched the rare disease company, Shire for portfolio expansion to a new therapeutic area for initial ophthalmology product entry to market within a highly competitive landscape.

Leverkusen, North Rhine-Westphalia, De

I directed the global medical affairs strategy for EYLEA® across 56 ex-US markets, advancing regulatory approval to launch product across 4 Retinal Therapeutic Areas including Wet AMD, CRVO, DME, and Myopic CNV). Optimally executed clinical development trials, Strategically designed and operationally executed post approval clinical trial requirements to efficiently satisfy compliance obligations. To Streamline Evidence Generation, I reduced the review period for investigator-initiated research from nine months to 30 days and expanded post-marketing surveillance efforts. In parallel, I created a joint company committee alliance on IIT Guidance to serve as roadmap for strategically aligned study concepts resulting in an IIT commitment increased from 36 to 104 Research and Clinical studies. Optimized Retinal AntiVEGF chronic treatment regimen by designing and executing the very first Treat & Extend RCTs to substantiate a treatment paradigm shift from the previous reactive PRN regimen to proactive Treat & Extend for long term management and individualized patient care thus successfully evolving patient centricity in Retinal Disease to reduce treatment burden and advance patient health outcomes. Generated New Data by Observational Studies and HEOR for promotional claims to demonstrate value proposition Cultivating 5 new PIVs, 3 new Database Registries, 3 new PASSs and oversaw 4 ongoing PMSs and 2 PASSs.

Geneva, Switzerland, Ch

At Alcon Laboratories, I led the global brand development across Pharma, Medical Devices, and Vision Care managing the entire lifecycle from concept through to market launch. I ensured rigorous compliance with FDA, CE Mark, and international regulatory standards, guiding the products through clinical trials and market entry. My role involved overseeing global medical education initiatives, gathering critical product efficacy data that informed high-level strategic decisions. Additionally, I authored over 20 publications that validated post-marketing studies and helped enhance the scientific credibility of our products. Ensured successful regulatory pathways for worldwide coverage in multiple jurisdictions for FDA approval in US, EU declaration, Japan, China, Brazil, Canada Australia, UAE, Saudi Arabia. Generated comprehensive medical affairs launch readiness strategic & operational plans for post approval product growth and lifecycle management through KOL engagement, medical education, medical information, medical communication. Delivered medical affairs excellence elevating brand recognition by distinct product differentiation for impactful product positioning and scientific messaging.

Elkins Park, Pa, Us

As a Professor at the Pennsylvania College of Optometry, I played a crucial role in shaping the future of optometry education. I developed advanced curricula that incorporated the latest research in visual science and optometric practices. I also mentored students and junior faculty, fostering a collaborative learning environment that encouraged academic excellence and clinical expertise. My involvement in research led to several published studies, contributing to the broader field of optometry and vision science.

Auburn, Nsw, Au

As an MD/OD at Opticare, I provided comprehensive eye care services, diagnosing and treating a range of ocular conditions. I oversaw the complex fittings of specialty contact lenses, low vision rehabilitation, and managing patients with complex visual needs. Additionally, I worked closely with a team of healthcare professionals to co-manage patients with systemic conditions affecting their vision, such as diabetes and hypertension. My focus on patient education and personalized care helped improve patient outcomes and satisfaction.

Charlotte, North Carolina, Us

As a Clinical Examiner for the NBEO, I played a critical role in evaluating the clinical competencies of aspiring optometrists. I was responsible for assessing candidates in various practical skills, including diagnostic techniques, patient communication, and clinical decision-making. My contributions helped ensure that future optometrists met the highest standards of practice, safeguarding public health and advancing the profession.

As the founder of the School of Optometry in Utrecht, I developed a comprehensive academic program from the ground up, ensuring that it met international standards for optometric education. I was responsible for curriculum development, faculty recruitment, and securing partnerships with local healthcare providers for student clinical placements. My leadership helped establish the school as a leading institution for optometric education in Europe, with a strong focus on research and clinical training.

Master Of Science - Ms, Clinical Pharmacology

Doctor Of Optometry - Od

Bachelor Of Science - Bs, Visual Science

Bachelor Of Arts - Ba, Biology